{"product_id":"daiichisankyo-pestle-analysis","title":"Daiichi Sankyo PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE Analysis for Daiichi Sankyo maps political, economic, social, technological, legal and environmental forces shaping strategic risk and growth opportunities. Ideal for investors, consultants and managers seeking actionable intelligence. Purchase the full report to download an editable, expert-ready assessment now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing and reimbursement policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational price controls, HTAs and value-based frameworks shape revenue for innovative drugs; global pharma sales were ~$1.6T in 2024. Daiichi Sankyo must manage Japan's biennial NHI revisions, US Medicare negotiation under the IRA (≈$100B savings over a decade) and EU HTA harmonization from Jan 2025. Cost-effectiveness thresholds can compress margins; proactive evidence and outcomes contracts mitigate risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment and approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDivergent standards across FDA (priority review 6 vs standard 10 months), EMA (centralized review ~210 days), PMDA (Sakigake\/priority ~6 months) and China NMPA (priority review ≈6 months) materially affect Daiichi Sankyo’s oncology and CV timelines. Harmonization and accelerated pathways speed access for high unmet-need therapies, but political pressure for faster cancer approvals raises post-market evidence and confirmatory trial demands. Strong global regulatory strategy and CMC readiness reduce delay risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics and supply-chain security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrade tensions, export controls, and sanctions have tightened access to APIs, biologics inputs and trial site operations, with China and India supplying over 60% of global APIs (industry estimates, 2023–24). Localization pressures push Daiichi Sankyo toward regional manufacturing and dual sourcing to protect oncology supply chains. Political instability in key sourcing countries risks disruptions to critical oncology products. Risk mapping and proactive government engagement are essential for resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic healthcare funding priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic healthcare funding steers market access for Daiichi Sankyo: oncology and chronic-disease allocations drive volume as the global oncology market reached about $220B in 2024, while Japan’s 65+ population is ~29% in 2024, prompting supportive cancer funding but tighter price scrutiny amid fiscal limits; election cycles shift spending toward prevention or generics, and alignment with national cancer plans boosts formulary inclusion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOncology share ~20% of pharma spend (2024)\u003c\/li\u003e\n\u003cli\u003eJapan 65+ ≈29% (2024)\u003c\/li\u003e\n\u003cli\u003eElection-driven shifts: prevention\/generics\u003c\/li\u003e\n\u003cli\u003eAlign with national cancer plans → higher formulary access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and innovation incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatent term extensions (SPC up to 5 years in the EU; US patent term adjustment\/extension up to 5 years) and data exclusivity vary by jurisdiction (US biologics exclusivity 12 years; EU orphan exclusivity 10 years; US orphan exclusivity 7 years), while political debates on TRIPS waivers and compulsory licensing since 2020–24 can threaten biologics and ADC commercial returns; strong IP regimes attract R\u0026amp;D and manufacturing investment and active policy advocacy preserves innovation-based returns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSPC up to 5 years\u003c\/li\u003e\n\u003cli\u003eUS biologics exclusivity 12 years\u003c\/li\u003e\n\u003cli\u003eEU orphan exclusivity 10 years, US orphan 7 years\u003c\/li\u003e\n\u003cli\u003eWaiver\/compulsory licensing debates 2020–24 affect ADCs\/biologics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma pricing pressure, HTA reforms and API concentration force localization and dual sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational price controls, HTAs and US Medicare negotiation under the IRA (≈$100B savings decade) constrain pricing while Japan NHI revisions and EU HTA from Jan 2025 affect launches. Regulatory timelines vary (FDA priority ~6 months, EMA ~210 days, PMDA Sakigake ~6 months) impacting oncology\/CV access. Trade tensions and API concentration (China+India \u0026gt;60% 2023–24) force localization and dual sourcing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal pharma sales\u003c\/td\u003e\n\u003ctd\u003e$1.6T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology market\u003c\/td\u003e\n\u003ctd\u003e$220B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan 65+\u003c\/td\u003e\n\u003ctd\u003e≈29% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs from China+India\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRA savings\u003c\/td\u003e\n\u003ctd\u003e≈$100B\/decade\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely affect Daiichi Sankyo, with data‑backed trends and region‑specific regulatory context; designed to help executives, consultants and investors identify risks, opportunities and scenario‑ready strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Daiichi Sankyo that’s easy to drop into presentations, editable for region or business-line notes, and ideal for quick team alignment on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic cycles and demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecessions tighten healthcare budgets but historically shield essential oncology and cardiovascular therapies, preserving demand; US healthcare spending reached about 19.7% of GDP in 2022, underscoring resilience in core markets. Deferred diagnostics shift treatment timing and mix, raising short-term volatility in oncology volumes. Persisting inflation (US CPI ~3.4% in 2024) increases input and logistics costs, squeezing margins. A balanced portfolio across indications stabilizes revenue through cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo’s USD\/EUR-denominated sales versus JPY\/EUR\/USD cost base creates material FX exposure; USD\/JPY moved roughly 140–160 and EUR\/USD about 0.95–1.10 in recent years, which can swing reported JPY earnings and reduce investment capacity. Natural hedges from global revenue mix and active financial hedging programs limit volatility, while dynamic pricing and sourcing strategies are tuned to prevailing FX trends to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer mix and affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising cost-sharing—with over one-third of US workers in high-deductible plans—reduces specialty drug uptake even as specialty medicines account for \u0026gt;50% of US drug spend, pressuring Daiichi Sankyo revenues. Tiered pricing and patient assistance programs expand access while protecting average selling prices. European reference pricing and tender dynamics can compress net prices by up to ~30% in some markets. Strong real-world evidence, used by \u0026gt;60% of HTA bodies by 2024, supports premium positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D productivity and capital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLate-stage oncology trials can exceed $200–300 million per program, forcing disciplined portfolio governance at Daiichi Sankyo. Success of ADC platforms like Enhertu, which exceeded $5 billion in global sales in 2024, shows shared technology cores can improve risk-adjusted returns. Partnering and co-commercialization (eg with AstraZeneca) de-risk capital needs while splitting economics, and kill-fast decisions preserve R\u0026amp;D ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh trial cost: \u0026gt;$200–300M per late-stage oncology program\u003c\/li\u003e\n\u003cli\u003eADC upside: Enhertu \u0026gt;$5B sales in 2024\u003c\/li\u003e\n\u003cli\u003ePartnering splits capital\/economics; kill-fast preserves ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising healthcare spend in Asia and LATAM expands addressable markets for chronic and cancer care; IQVIA data show emerging markets accounted for about 60% of global medicine consumption growth in 2024, boosting opportunity for Daiichi Sankyo’s oncology and cardiovascular franchises. Pricing corridors and local partnerships are key to penetration, while economic volatility and reimbursement delays require working-capital agility and flexible procurement. Tailored access models, including managed-entry and tiered pricing, accelerate uptake in these regions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmerging-market growth: tag:IQVIA-60%-2024\u003c\/li\u003e\n\u003cli\u003ePricing \u0026amp; partnerships: tag:localization\u003c\/li\u003e\n\u003cli\u003eWorking capital: tag:reimbursement-risk\u003c\/li\u003e\n\u003cli\u003eAccess models: tag:managed-entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma pricing pressure, HTA reforms and API concentration force localization and dual sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecession-resilient demand: US health spend ~19.7% of GDP (2022) keeps oncology\/cardiovascular volumes firmer. Inflation and logistics (US CPI ~3.4% in 2024) squeeze margins; FX (USD\/JPY ~140–160; EUR\/USD 0.95–1.10) swings reported JPY earnings. Late-stage oncology costs $200–300M; ADC upside (Enhertu \u0026gt;$5B in 2024) and emerging markets (IQVIA: ~60% of 2024 volume growth) diversify revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS health spend\u003c\/td\u003e\n\u003ctd\u003e19.7% (2022)\u003c\/td\u003e\n\u003ctd\u003eDemand resilience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI\u003c\/td\u003e\n\u003ctd\u003e~3.4% (2024)\u003c\/td\u003e\n\u003ctd\u003eCost pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/JPY\u003c\/td\u003e\n\u003ctd\u003e140–160\u003c\/td\u003e\n\u003ctd\u003eFX risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage cost\u003c\/td\u003e\n\u003ctd\u003e$200–300M\u003c\/td\u003e\n\u003ctd\u003eCapital intensity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging growth\u003c\/td\u003e\n\u003ctd\u003e~60% (IQVIA 2024)\u003c\/td\u003e\n\u003ctd\u003eMarket expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADC sales\u003c\/td\u003e\n\u003ctd\u003eEnhertu \u0026gt;$5B (2024)\u003c\/td\u003e\n\u003ctd\u003ePlatform upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDaiichi Sankyo PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis Daiichi Sankyo PESTLE Analysis preview is the exact, fully formatted document you’ll receive after purchase. The content, layout, and structure visible here are identical to the file you'll download—no placeholders or surprises. Use it immediately for strategic insight and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162590425465,"sku":"daiichisankyo-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/daiichisankyo-pestle-analysis.png?v=1762704057","url":"https:\/\/portersfiveforce.com\/products\/daiichisankyo-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}